CytomX delivered a solid full-year 2024 performance highlighted by collaboration-driven revenue growth and a meaningful cash runway extension into mid-2026. Total revenue for 2024 was $138.1 million, up meaningfully from $101.2 million in 2023, with gross profit effectively matching revenue (gross margin ~99%). The company reported net income of $18.9 million and earnings per share of $0.22 for the year, driven in part by milestone income from AbbVie and ongoing collaborations with BMS, Moderna, Estella, and Regeneron. Operating expenses were $113.1 million in 2024, up modestly versus 2023, with R&D activity totaling $83.4 million and G&A $29.7 million; excluding the AbbVie milestone, operating expenses were largely flat YoY, underscoring disciplined cost management as CytomX advances its pipeline.
Crucially, CytomX positioned 2025 as a watershed year for pipeline data generation and corporate value. Management highlighted two lead programs advancing into the clinic in 2024—CX-2051 (masked EPCAM-targeted ADC) and CX-801 (masked interferon alpha 2b). The company reiterated plans to publish initial Phase 1a data for CX-2051 in colorectal cancer during the first half of 2025, with continued escalation and data readouts expected in the second half of 2025. CX-801 is progressing through a Phase 1 dose-escalation in advanced melanoma, with translational data anticipated in H2 2025 and potential initiation of KEYTRUDA combination therapy in 2025 under Merck collaboration.
Liquidity remains robust with $100.6 million in cash, cash equivalents, and investments at year-end 2024, supporting a cash runway into Q2 2026. The company explicitly notes that its cash guidance does not assume additional milestones from existing collaborations. The balance sheet reflects substantial non-operating asset impact from collaboration milestones and a positive near-term outlook tied to its pipeline milestones. Investors should weigh CytomX’s strong near-term liquidity and marquee pipeline milestones against the inherent development risk common to early-stage oncology programs and the reliance on partner collaborations for future value creation.